A Brazilian experience of the self transglutaminase-based test for celiac disease case finding and diet monitoring

Table 2 Demographic data, correlation with antiendomysium antibodies, endoscopic and histological findings of duodenal biopsies for the positive individuals

	Age	Gender	IgA EmA	Biopsy	IEL	Endoscopy
Celiac at diagnosis
CPA	28	F	Positive	III-C	> 40	Scalloped folds, nodularity
CBO	38	F	Positive	III-C	40	Mosaic pattern
NHF	41	F	Positive	III-C	> 40	Nodularity, atrophic areas
AHR	42	M	Positive	III-C	45	Erosions, edema
HB	61	M	Negative	III-C	> 40	Decreased folds
GFD transgression
GSCS	10	M	Positive	III-C	55	Decreased folds, atrophic areas
ALM	19	F	Positive	III-A	NC	Atrophic areas
VC	23	F	Positive	III-C	> 40	Atrophic areas
FA	23	M	Positive	III-C	35	Decreased folds, atrophic areas
LGH	31	F	Positive	III-A	35	Decreased folds
RK	38	F	Positive	III-C	> 50	Atrophic areas
First-degree relatives
LGS	21	F	Positive	I	38	Normal
RG	48	F	Positive	III-C	48	Atrophy of folds
ERA	52	F	Negative	R	R	R
Dyspepsia
EJMS	21	F	Positive	III-A	50	Atrophy
LA	26	F	Positive	III-C	> 40	Scalloped folds, areas of atrophy

EmA: Antiendomysium; IEL: Percent of intraepithelial lymphocytes; NC: Not counted; R: Recommended.